Nutritional Intake and Gut Microbiome

February 25, 2019 updated by: Ky Young Cho, Hallym University Kangnam Sacred Heart Hospital

Nutritional Intake, Metabolic Abnormalities and Gut Microbiome in Children

Pediatric obesity has been increasing in prevalence, but concerns have been raised around the world because no treatment has been found. Recently, however, research on gut microbiome has begun to become a new alternative. It has been shown that changes in the microbiome in adults may induce obesity. However, the results on children are still scarce. Unlike adults, children have few external factors such as alcohol, tobacco, stress, and cancer, making them suitable for obesity-related gut microbiome studies. The investigators will use Illumina MiSeq platform for 16s rRNA metagenomics profiling in children. In this study, the investigators aimed to analyze the relationship between pediatric obesity, gut microbiome profile, blood biomarkers relevant to metabolic syndrome, and nutrient intake data.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

61

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Seoul, Korea, Republic of, 07440
        • Hallym University Kangnam Sacred Heart Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 12 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Primary care clinic and community samples

Description

Inclusion Criteria:

  • Obese children: Children ≥95 ‰ between age 7 and 12 years
  • Non-obese children: 5‰<BMI <85 ‰ for children between the ages of 7 and 12 years

Exclusion Criteria:

  • Taking antibiotics, probiotics, or steroids for a month before visit
  • Taking probiotics-like products including yogurt for seven days before visit
  • Having enteritis symptoms including diarrhea for a month before visit
  • Chronic heart disease, chronic bowel disease, chronic liver disease, chronic kidney disease, endocrine disease, genetic diseases or congenital metabolic disorder

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Obese children
Children ≥95 ‰ between age 7 and 12 years
Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
Other Names:
  • 16s metagenomic analysis
Non-obese children
5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
Other Names:
  • 16s metagenomic analysis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of fecal microbial profile with childhood obesity
Time Frame: visit 1day
Analysis of fecal microbial profile using 16s rRNA sequencing
visit 1day
Correlation of fecal microbial profile with nutrient intake data using feeding diary
Time Frame: visit 1day
Nutritional intake analysis of total calorie, carbohydrate, fiber, fat, and protein from feeding dairy for two days
visit 1day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of childhood obesity with metabolic abnomalities using blood sampling
Time Frame: visit 1day
Glucose, AST, ALT, uric acid, triglyceride, HDL-cholesterol, LDL-cholesterol, total cholesterol, insulin, hsCRP, 25(OH)-Vitamin D3, hemoglobin, ferritin, and HbA1c
visit 1day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ky Young Cho, M.D., Kangnam Sacred Heart Hospital, Hallym University College of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2017

Primary Completion (Actual)

October 12, 2018

Study Completion (Actual)

October 12, 2018

Study Registration Dates

First Submitted

December 19, 2017

First Submitted That Met QC Criteria

December 24, 2017

First Posted (Actual)

January 3, 2018

Study Record Updates

Last Update Posted (Actual)

February 27, 2019

Last Update Submitted That Met QC Criteria

February 25, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • Gut microbiome

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Study participants will only agree if IPD is not shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Childhood

Clinical Trials on Gut microbiome profiling

Subscribe